Roivant CFO Maintains Strong Position with 399K Shares After RSU Settlement

Rhea-AI Filing Summary

Roivant Sciences CFO Richard Pulik reported a Form 4 filing on June 28, 2025, disclosing a transaction dated June 20, 2025. The filing details the following key transaction:

• Disposed of 1,503 common shares at a price of $11.45 per share through a "net settlement" transaction (Code F)
• The transaction was related to tax withholding obligations from the vesting and settlement of previously granted RSUs
• Following the transaction, Pulik directly owns 399,056 common shares

The filing was signed by Jo Chen as Attorney-in-Fact for Richard Pulik on June 24, 2025. This routine transaction represents standard tax withholding practices for executive RSU settlements and does not indicate a discretionary sale by the insider.

Insider Trade Summary

1 transaction reported

Mixed 1 txn

Insider Pulik Richard

Role CFO

Type	Security	Shares	Price	Value
Tax Withholding	Common Shares	1,503	$11.45	$17K

Holdings After Transaction: Common Shares — 399,056 shares (Direct)

Footnotes (1)

1. [object Object]

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Form 4 Insider Transactions: What Each Field Means →

Accepted by SEC EDGAR 06/24/2025 - 09:01 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Pulik Richard

(Last) (First) (Middle)

C/O ROIVANT SCIENCES LTD.

7TH FLOOR, 50 BROADWAY

(Street)

LONDON X0 SW1H 0DB

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Roivant Sciences Ltd. [ ROIV ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	CFO

3. Date of Earliest Transaction (Month/Day/Year)
06/20/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Shares	06/20/2025		F		1,503(1)	D	$11.45	399,056	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Represents the "net settlement" by the Issuer of RSUs previously granted to the reporting person in order to satisfy applicable tax withholding obligations in connection with the vesting and settlement of such RSUs.

	By: /s/ Jo Chen, as Attorney-in-Fact for Richard Pulik	06/24/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transaction did ROIV's CFO Richard Pulik report on June 20, 2025?

CFO Richard Pulik reported the disposition of 1,503 common shares at a price of $11.45 per share through a 'net settlement' transaction (code 'F'). This was related to tax withholding on vesting RSUs. Following the transaction, he retained beneficial ownership of 399,056 common shares.

How many ROIV shares does CFO Richard Pulik own after the June 2025 transaction?

After the reported transaction, Richard Pulik directly owns 399,056 common shares of Roivant Sciences Ltd. (ROIV). All shares are held in direct ownership form.

What was the purpose of ROIV CFO's share disposition in June 2025?

The share disposition was a 'net settlement' by Roivant Sciences to satisfy tax withholding obligations related to the vesting and settlement of Richard Pulik's RSUs (Restricted Stock Units). This is a common practice for handling tax obligations on vesting equity awards.

What was the transaction price for ROIV shares in CFO Pulik's Form 4 filing?

The reported transaction price for the shares was $11.45 per share, with 1,503 shares being disposed of through a net settlement transaction on June 20, 2025.